Biotech News
Filter News
Found 520,763 articles
-
A summary of IPOs from companies in the biotech and pharma world since March 1, 2019.
-
Stanford University researchers kicked off the annual meeting of the American College of Cardiology (ACC) with a very large study of more than 400,000 patients in a trial sponsored by Apple.
-
It’s a busy week for the U.S. Food and Drug Administration (FDA) with quite a number of pending drug approvals, several of which were delayed for a variety of reasons. Here’s a look.
-
March is women’s History Month, with March 8 designated as International Women’s Day. Let’s take a look at 10 pioneers, some still alive, and some who are no longer with us, who are pioneers in the field of biotechnology.
-
The latest financing round will boost the study of KarXT, Karuna’s lead product candidate, which is currently in Phase II development as a potential treatment for acute psychosis in patients with schizophrenia.
-
QxMD Adds Mobile-First Continuing Medical Education (CME) Programming to Its HCP Content Engagement Platform
3/18/2019
In addition to earning CME credits for literature searches, busy healthcare professionals (HCPs) can now also acquire credits through mobile learning courses in a matter of minutes each day.
-
Ono Pharmaceutical and twoXAR Announce Drug Discovery Research Collaboration
3/18/2019
Ono Pharmaceutical Co., Ltd. announced that the companies have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease.
-
Nutrition Research Publishes Study Showing Kemin Neumentix® Product Improves Focus
3/18/2019
Peer-reviewed journal Nutrition Research recently published new clinical science supporting cognitive performance with Neumentix®, a high-polyphenol nootropic ingredient from Kemin Human Nutrition and Health.
-
Horizon Pharma plc Wins PR News CSR Award for Partnership with Perspectives Math and Science Academy
3/18/2019
Horizon Pharma plc announced that it has won a PR News CSR Award in the Corporation category for its impactful partnership with Chicago-based charter school, Perspectives Math and Science Academy.
-
New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Approved for Australian Women(1)
3/18/2019
A NEW drug shown to significantly reduce the risk of cancer recurrence or death in an aggressive form of breast cancer has today been approved for use in Australian patients.
-
ArunA Bio Appoints Al Medwar as Executive Vice President, Corporate and Commercial Development
3/18/2019
ArunA Bio, a leader in the development of exosomes and exosome therapeutics for the treatment of neurodegenerative disorders, announced the appointment of Al Medwar as Executive Vice President, Corporate and Commercial Development.
-
Wounded Warrior Project Empowers Veterans Through The Honor Foundation
3/18/2019
Wounded Warrior Project® (WWP) announces a new partnership with The Honor Foundation (THF), a nonprofit that has developed a nationally recognized transition program for the military's special operations forces community.
-
Takeda Receives U.S. FDA Approval to Manufacture FLEXBUMIN® at New Plasma Manufacturing Facility near Covington, Georgia
3/18/2019
FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is indicated for hypovolemia, hypoalbuminemia, (burns, Adult Respiratory Distress Syndrome (ARDS), and nephrosis), cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN). Albumin is not indicated as an intravenous nutrient
-
CBD Oil May Help With ADHD, BestCBDOils Ranks the Best Products to Try
3/18/2019
During a nationwide shortage of ADHD medications that is the worst the country has seen since the year 2012, there may be another treatment option to consider. CBD has been making waves across the country as more research is conducted and published, and more people are turning to this plant medicine for relief from a variety of problems ranging from anxiety to chronic pain.
-
U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy
3/18/2019
Aimmune Therapeutics, Inc. announced that the Biologics License Application (BLA) for AR101 has been accepted for review by the U.S. Food and Drug Administration (FDA).
-
Fluoride Can Cause Degenerative Eye Diseases, Study Shows
3/18/2019
Fluoride contributes to degenerative eye diseases such as cataracts, age related macular degeneration (AMD) and glaucoma, reports DT Waugh in the International Journal of Environmental Research and Public Health (March 2019), reports New York State Coalition Opposed to Fluoridation, Inc. (NYSCOF).
-
Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options - March 18, 2019
3/18/2019
An individual participant in Nordic Nanovector ASA's previous share option program, not being a primary insider, has exercised a total number of 17,392 options through exercise of a corresponding number of free-standing warrants. 14,374 of the options are exercised at a strike price of NOK 30.00 per share, and 3,018 of the options are exercised at a strike price of NOK 14.24.
-
Matinas BioPharma to Present at the 31st Annual ROTH Conference
3/18/2019
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present at the 31st Annual ROTH Conference on Tuesday, March 19 at 2:30 PM PT in Dana Point, CA.
-
Medical Diagnostic Laboratories, L.L.C., Fights Tick- and Mosquito-borne Epidemic with New Comprehensive Testing for Vector-borne Disease
3/18/2019
Medical Diagnostic Laboratories, L.L.C., (MDL), a Genesis Biotechnology Group® (GBG) company and CLIA-certified, CAP-accredited laboratory specializing in high-complexity, state-of-the-art, automated DNA-based molecular analyses, has expanded its testing to include a comprehensive program for the detection of vector-borne diseases.
-
California Life Sciences Association (CLSA) Appoints Andrew Setikas as Senior Vice President of Business Development and Strategy
3/18/2019
Life Sciences Industry Leader Andrew Setikas to Take the Helm of CLSA’s Business Development, Membership and Strategic Alliance Activities